Federal Circuit: Claim Amendments During IPR That Respond to Grounds of Unpatentability May Also Make Changes Unrelated to the IPR

Dec 1, 2022

Reading Time : 1 min

In American National Manufacturing, Inc. v. Sleep Number Corp, the appellant-petitioner American National argued that the PTAB erred in its application of 37 C.F.R. § 42.121 when it permitted Sleep Number to include certain claim amendments to “achieve consistency and accuracy in terminology and phrasing throughout the patent family.” Section 42.121 specifies that a motion to amend may be denied where “[t]he amendment does not respond to a ground of unpatentability involved in the trial.” In applying this regulation, the PTAB determined that any claim amended to address a ground of unpatentability could also be amended for other reasons, including potential § 101 and § 112 issues.

On appeal, American National argued the Board violated due process and the APA by allowing additional amendments in the context of an IPR. More specifically, American National argued it would be unfair and asymmetrical to allow patentees to use an IPR as a vehicle to amend claims to address § 101 or § 112 issues when petitioners cannot challenge claims on those grounds.

The Federal Circuit, however, disagreed. Citing previous decisions, the court noted that petitioners are free to challenge amended claims on grounds that go beyond § 102 and § 103, including on § 101 and § 112. Thus, it discerned no asymmetry between patentees and petitioners in the context of a motion to amend. And because each of the amended claims contained an amendment responsive to a ground of unpatentability raised in the IPR proceeding, Sleep Number’s additional amendments were not improper.

Practice Tip: For patentees facing co-pending litigation and IPR proceedings, there may be an opportunity to amend claims to defeat both the IPR petition and live defenses in the litigation. It is important, however, to weigh that value of such a result against the risk of possible invalidation or intervening rights. And, similarly, defendants considering filing an IPR petition must weigh the possibility that the Patent Owner might use a motion to amend to remedy potential § 112 deficiencies.

American National Manufacturing, Inc. v. Sleep Number Corporation, Case Nos. 2021-1321

Share This Insight

Previous Entries

IP Newsflash

July 22, 2026

The Court of Federal Claims recently denied the United States’ motion to dismiss a patent infringement suit related to production of a COVID-19 vaccine. The court held that it had jurisdiction because the plaintiff filed its claim there before it filed a parallel suit in a district court and because it adequately pleaded the government’s involvement.

...

Read More

IP Newsflash

July 13, 2026

In a precedential and sua sponte Director Review decision, USPTO Director Squires recently vacated three related institution decisions nearly six months after institution where a district court later found the challenged claims invalid. Because the fourteen-day deadline to request Director Review of the institution decisions had passed, the Director used this opportunity to formally extend the deadline in two ways. First, he extended the fourteen-day deadline under 37 C.F.R. § 42.75(c)(1) to thirty days, which “puts requests for Director Review of decisions to institute trial on equal footing to requests for Director Review of final decisions or decisions not to institute trial.” Second, he outlined certain “exceptional circumstances” that warrant a further extension of the deadline to account for changes in the case that “surface after the deadline.” In the case at hand, the Director found the district court’s invalidity finding to be such an “exceptional circumstance” and ultimately initiated review and vacated the institution decisions on that basis.

...

Read More

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.